Adaptive BiotechnologiesADPT
ADPT
About: Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
Employees: 619
0
Funds holding %
of 7,299 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
116% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 19
32% more capital invested
Capital invested by funds: $859M [Q4 2024] → $1.14B (+$278M) [Q1 2025]
9% more funds holding
Funds holding: 207 [Q4 2024] → 226 (+19) [Q1 2025]
5.84% more ownership
Funds ownership: 97.09% [Q4 2024] → 102.93% (+5.84%) [Q1 2025]
9% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 67
3% more call options, than puts
Call options by funds: $383K | Put options by funds: $372K
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$9
13%
downside
Avg. target
$10.67
4%
upside
High target
$13
26%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
Piper Sandler David Westenberg | 26%upside $13 | Overweight Maintained | 6 May 2025 |
Morgan Stanley Tejas Savant | 13%downside $9 | Equal-Weight Maintained | 5 May 2025 |
Goldman Sachs Salveen Richter | 3%downside $10 | Buy Maintained | 2 May 2025 |
Financial journalist opinion
Based on 5 articles about ADPT published over the past 30 days
Positive
Zacks Investment Research
3 days ago
What Makes Adaptive Biotechnologies (ADPT) a New Buy Stock
Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Positive
Zacks Investment Research
5 days ago
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?
Here is how Adaptive Biotechnologies (ADPT) and CVS Health (CVS) have performed compared to their sector so far this year.
Neutral
GlobeNewsWire
2 weeks ago
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers
SEATTLE, May 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in 30 presentations, including a total of 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago and the European Hematology Association (EHA) Congress taking place June 12-15 in Milan. These presentations include notable new data supporting the clinical actionability of clonoSEQ in both multiple myeloma (MM) and chronic lymphocytic leukemia (CLL).
Neutral
GlobeNewsWire
2 weeks ago
Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL.
Positive
Zacks Investment Research
3 weeks ago
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?
Here is how Adaptive Biotechnologies (ADPT) and CVS Health (CVS) have performed compared to their sector so far this year.
Positive
Zacks Investment Research
1 month ago
Adaptive Biotechnologies (ADPT) is a Great Momentum Stock: Should You Buy?
Does Adaptive Biotechnologies (ADPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Positive
Zacks Investment Research
1 month ago
Does Adaptive Biotechnologies (ADPT) Have the Potential to Rally 26.45% as Wall Street Analysts Expect?
The consensus price target hints at a 26.5% upside potential for Adaptive Biotechnologies (ADPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Positive
Zacks Investment Research
1 month ago
Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year?
Here is how Adaptive Biotechnologies (ADPT) and Centene (CNC) have performed compared to their sector so far this year.
Neutral
Seeking Alpha
1 month ago
Adaptive Biotechnologies Corporation (ADPT) Q1 2025 Earnings Call Transcript
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Karina Calzadilla - Head of Investor Relations & FP&A Chad Robins - Chief Executive Officer & Co-Founder Kyle Piskel - Chief Financial Officer Susan Bobulsky - Chief Commercial Officer Conference Call Participants Mark Massaro - BTIG David Westenberg - Piper Sandler Yuko Oku - Morgan Stanley Sebastian Sandler - JPMorgan Tom Stevens - TD Cowen Corey Rosenbaum - Scotia Bank Maggie Boeye - William Blair Operator Good day, and thank you for standing by. Welcome to the Adaptive Biotechnologies First Quarter 2025 Earnings Conference Call.
Positive
Zacks Investment Research
1 month ago
Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Charts implemented using Lightweight Charts™